ACOG 委员会意见第751号摘要:人类免疫缺陷病毒感染女性的分娩与产程管理
本委员会意见更新了感染人类免疫缺陷病毒(HIV)孕妇的孕期及分娩管理建议,以预防母婴传播。持续研究提示相当数量围产期HIV传播源于分娩过程中胎儿暴露于病毒。联合抗逆转录病毒治疗且母体病毒载量持续≤1,000拷贝/mL时,母婴传播风险可达1-2%或更低,与分娩方式或破膜时长无关。
要点
- 联合抗逆转录病毒治疗且病毒载量≤1,000拷贝/mL的HIV感染孕妇,阴道分娩是合适的。
- 高病毒载量者可在临产及破膜前行择期剖宫产,并联合围产期母体抗逆转录病毒治疗以降低传播风险。
- 应与每位HIV感染孕妇尽早讨论择期剖宫产选项及其在病毒抑制不佳时的优势,尊重其分娩方式决定。
核心结论
- 联合抗逆转录病毒治疗使母体病毒载量持续≤1,000拷贝/mL时,母婴传播风险可达1-2%或更低,与分娩方式或破膜时长无关。
- 高病毒载量HIV感染孕妇可通过临产及破膜前择期剖宫产联合围产期母体抗逆转录病毒治疗降低母婴传播风险。
研究设计与样本
- 美国妇产科医师学会(ACOG)委员会意见,基于既有及持续研究更新孕期与分娩管理建议。
主要发现
- 持续研究提示相当数量围产期HIV传播病例源于分娩过程中胎儿暴露于病毒,确切机制尚不清楚。
- 联合抗逆转录病毒治疗且母体病毒载量持续≤1,000拷贝/mL时,母婴传播风险可达1-2%或更低,与分娩方式或破膜时长无关。
关键数值与推荐
- 联合抗逆转录病毒治疗且分娩时或临近分娩时病毒载量≤1,000拷贝/mL的HIV感染孕妇,阴道分娩是合适的。
- 高病毒载量者行临产及破膜前剖宫产(本文称择期剖宫产)并联合围产期母体抗逆转录病毒治疗可降低母婴传播风险。
- 应与每位HIV感染孕妇尽早讨论择期剖宫产选项及其在病毒抑制不佳时的优势,使其有机会提问并考虑分娩计划决策。
- 讨论母体与新生儿风险后,应尊重患者对分娩方式的选择。
临床怎么用
- 对联合抗逆转录病毒治疗且病毒载量≤1,000拷贝/mL的HIV感染孕妇,阴道分娩是合适的。
- 对高病毒载量者,可考虑临产及破膜前择期剖宫产联合围产期母体抗逆转录病毒治疗以降低母婴传播风险。
- 应与每位HIV感染孕妇尽早讨论择期剖宫产选项及其在病毒抑制不佳时的优势,尊重其分娩方式决定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This Committee Opinion is being revised to provide updated guidance on the management of pregnant women during pregnancy and delivery to prevent mother-to-child transmission of the human immunodeficiency virus (HIV). Prevention of transmission of HIV from the woman to her fetus or newborn is a major goal in the care of pregnant women infected with HIV. Continuing research into mother-to-child transmission of HIV has suggested that a substantial number of cases of perinatal HIV transmission occur as the result of fetal exposure to the virus during labor and delivery. The precise mechanisms are not known. Established and ongoing research has shown that treatment of HIV-infected pregnant women with combined antiretroviral therapy can achieve a 1-2% or lower risk of mother-to-child transmission if maternal viral loads of 1,000 copies/mL or less can be sustained, independent of the route of delivery or duration of ruptured membranes before delivery. Vaginal delivery is appropriate for HIV-infected pregnant women who have been maintained on combined antiretroviral therapy and who have viral loads of 1,000 copies/mL or less at or near delivery. The risk of mother-to-child transmission in HIV-infected women with high viral loads can be reduced by performing cesarean deliveries before the onset of labor and before rupture of membranes (termed scheduled cesarean delivery in this document), in conjunction with the use of peripartum maternal antiretroviral therapy. Discussion of the option of scheduled cesarean delivery and its advantages in the situation of suboptimal viral suppression should begin as early as possible in pregnancy with every pregnant woman with HIV infection to give her an adequate opportunity to ask questions and consider her decision-making concerning the delivery plan. The patient's decision regarding her route of delivery should be respected after maternal and neonatal risks have been discussed.
引用
- ACOG Committee Opinion No. 751 Summary: Labor and Delivery Management ofWomenWith Human Immunodeficiency Virus Infection. Obstet Gynecol. 2018. PMID: 30134420. doi:10.1097/AOG.0000000000002821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。